Related Experiment Videos
Cardiopulmonary bypass-induced inflammation: is it important?
1Department of Anesthesiology, University of Nebraska Medical Center, Omaha 68198-4455, USA.
Journal of Cardiothoracic and Vascular Anesthesia
|May 16, 1998
Summary
Cardiopulmonary bypass (CPB) triggers inflammation via cytokines, leading to neutrophil activation and nitric oxide (NO) release. Therapies like hemofiltration and aprotinin show promise in mitigating CPB-induced inflammation and improving patient outcomes.
Area of Science:
- Cardiovascular Surgery
- Immunology
- Biomedical Engineering
Background:
- Cardiopulmonary bypass (CPB) induces systemic endotoxemia, stimulating pro-inflammatory cytokine release (TNF-alpha, IL-1, IL-6).
- Elevated IL-6 correlates with post-CPB left ventricular dysfunction and myocardial ischemia.
- Neutrophil-endothelial adhesion, mediated by CD11b integrins and ICAM-1, contributes to CPB-related inflammation and organ injury.
Purpose of the Study:
- To explore the relationship between CPB-induced inflammation, neutrophil activation, and nitric oxide (NO) synthesis.
- To evaluate the efficacy of various therapeutic strategies in mitigating CPB-related inflammatory responses.
Main Methods:
- Review of studies investigating CPB-induced cytokine release, neutrophil activation, and NO production.
- Analysis of data from interventions including hemofiltration, acadesine, and aprotinin.
Main Results:
- Hemofiltration during CPB in children reduced TNF-alpha and IL-6 levels, improving hemodynamics and oxygenation.
- Acadesine inhibited leukocyte CD11b upregulation, reducing adverse cardiovascular outcomes.
- Aprotinin reduced TNF-alpha levels, blunted neutrophil CD11b upregulation, and inhibited cytokine-induced NO synthase expression.
Conclusions:
- CPB-activated cytokine release, neutrophil activation, and increased NO synthesis are causally linked.
- Therapeutic interventions targeting inflammation, such as hemofiltration and aprotinin, demonstrate potential in managing CPB-associated complications.